Invention Grant
- Patent Title: Endotrophin neutralization and use thereof
-
Application No.: US15417740Application Date: 2017-01-27
-
Publication No.: US10221235B2Publication Date: 2019-03-05
- Inventor: Philipp Erich Scherer , Jiyoung Park , Zhiqiang An
- Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
- Applicant Address: US TX Austin
- Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
- Current Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
- Current Assignee Address: US TX Austin
- Agency: Parker Highlander PLLC
- Main IPC: C07H21/04
- IPC: C07H21/04 ; A61K39/395 ; C07K16/18 ; A61K33/24 ; A61K31/555 ; A61K39/00

Abstract:
Aspects of the present invention relate to methods and reagents for increasing chemosensitivity to platinum-based chemotherapy. In one aspect, a method of increasing chemosensitivity to platinum-based chemotherapy is provided, comprising administering to a patient in need thereof an effective amount of an endotrophin-neutralizing agent. The agent can be a monoclonal antibody, or fragment thereof, capable of binding to the C5 domain of the alpha3 chain of collagen VI. In some embodiments, the method can further include administering an effective amount of thiazolidinedione to said patient.
Public/Granted literature
- US20170267749A1 ENDOTROPHIN NEUTRALIZATION AND USE THEREOF Public/Granted day:2017-09-21
Information query